The health care market is failing to support new antibiotics used to treat some of the world’s most dangerous, drug-resistant “superbugs,” according to a new analysis by University of Pittsburgh School of Medicine infectious disease scientists.
In a study published today in Antimicrobial Agents and Chemotherapy, a journal of the American Society for Microbiology, investigators used nationwide prescription data to determine that the current annual U.S. sales of new antibiotics to treat carbapenem-resistant Enterobacteriaceae (CRE), one of the world’s most insidious drug-resistant bacteria, is about $101 million annually — significantly short of the $1 billion believed to be necessary to assure the financial viability of a new antibiotic. Even if new anti-CRE agents were used as widely as possible to treat CRE infections, the projected market size is only $289 million.
“New drugs against CRE address a major, previously unmet medical need and are critical to save lives. If the market can’t support them, then that is a chilling commentary on the future of antibiotic development,” said lead author Cornelius J. Clancy, M.D., associate professor of medicine and director of the mycology program and Extensively Drug Resistant Pathogen Laboratory in Pitt’s Division of Infectious Diseases. “Without antibiotics against increasingly resistant bacteria and fungi, much of modern medicine may become infeasible, including cancer chemotherapies, organ transplantation and high-risk abdominal surgeries.”
CRE infections are estimated to cause 1.5 to 4.5 million hospitalizations worldwide each year. The Centers for Disease Control and Prevention has classified CRE as urgent threat pathogens and calls them the “nightmare bacteria.” The World Health Organization and Infectious Disease Society of America have designated CRE as highest priority pathogens for development of new antibiotics.
Since 2015, five antibiotics against CRE have gained U.S. Food and Drug Administration approval and trials have so far shown three of them to be more effective and less toxic than the previous first-line antibiotics. One of the developers of the new anti-CRE drugs — the biopharmaceutical company Achaogen — declared bankruptcy in April because of its steep losses.
After reporting earlier this year that new CRE antibiotics are being prescribed in only about a quarter of infections that warrant them, Clancy and senior author M. Hong Nguyen, M.D., Pitt professor of medicine and director of UPMC’s Antimicrobial Management Program, investigated the market needed to make antibiotic development sustainable. They found a shortfall in revenue potential, evidenced by the financial difficulties faced by drug companies that created the new anti-CRE drugs.
“The prudent approach when fighting bacteria is to have multiple treatment options in the pipeline so that when resistance is inevitably developed to the current drug, a new antibiotic is waiting in the wings,” said Nguyen. “But we found that market prospects will become even more daunting if more anti-CRE drugs are approved, which is bad news for infectious disease physicians and, more importantly, our patients.”
Clancy and Nguyen propose a combination of “push” and “pull” incentives to encourage sustainable antibiotic development, starting with approval of the bilateral DISARM Act, which currently is under consideration in Congress. DISARM would assure full Centers for Medicare and Medicaid Services reimbursement for use of new antibiotics against resistant infections in hospitalized patients, rather than subsuming antibiotic costs into the discounted bundled payment hospitals receive. This would remove the disincentive hospitals face in using more effective but more expensive new agents rather than cheaper, older agents.
There also needs to be a cultural and behavioral change among hospitals and clinicians to encourage faster adoption and appropriate use of new antibiotics, the researchers said. Infectious disease physicians and pharmacists need to take responsibility for educating the wider clinical community about the importance of quickly updating and following guidelines on the best possible antibiotics to be using for their patients.
Learn more: New Study is ‘Chilling Commentary’ on Future of Antibiotics
The Latest on: The future of antibiotics
[google_news title=”” keyword=”the future of antibiotics” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: The future of antibiotics
- Why are so many young people getting cancer? Everything we know from 'ageing cells' to 'antibiotics'on April 27, 2024 at 6:15 am
Early-onset cancer cases are on the rise and are forecast to continue to surge in the next decade, with people in their 40s the most at risk. As scientists work to pinpoint the exact cause, experts ha ...
- What to Know About Pivya, the New Antibiotic Treatment for UTIson April 26, 2024 at 4:06 am
The Food and Drug Administration recently approved Pivya (pivmecillinam) to treat uncomplicated UTIs in female adults. Clinical trials show that Pivya is effective and side effects are limited.
- Study: Antibiotic use in patients hospitalized with COVID-19 appears to have no beneficial effect on clinical outcomeson April 25, 2024 at 3:10 pm
Antibiotic treatment of adults hospitalized with moderate COVID-19 is associated with clinical deterioration, despite the drugs being given to over 40% of patients, according to new research being ...
- A Vaccine to Fight Antibiotic Resistanceon April 25, 2024 at 2:25 pm
MSU, Harvard Medical School team up to expand vaccine science’s role in the fight against MRSA and other infections ...
- Can I take antibiotics and painkillers together? See the NHS adviceon April 25, 2024 at 3:24 am
Here is the health expert's advice regarding taking them with painkillers and the other key things you should avoid when taking antibiotics. The NHS has advised that is safe to take paracetamol with ...
- Researchers develop vaccine to fight antibiotic resistanceon April 24, 2024 at 11:37 pm
Driven by the overuse of antimicrobials, pathogens are quickly building up resistances to once-successful treatments. It’s estimated that antimicrobial-resistant infections killed more than 1 million ...
- Oral Antibiotics Market Dynamic Markets, Resilient Businesses A Guide to Future-Proofingon April 23, 2024 at 11:35 pm
The global oral antibiotics market is projected to grow at a compound annual growth rate (CAGR) of 3.2% during the forecast period 2021-2027, according to the new report published by Report Ocean ...
- Celine Dion Reveals How Her Iconic Wedding Headpiece Sent Her to the Doctoron April 23, 2024 at 1:25 pm
Celine Dion is recalling how she paid a physical price for her epic wedding look. In a video for Vogue, the singer looked back at some of her iconic outfits for the magazine's "Life in Looks" series, ...
- Infectious worms may offer insight into antibiotic and pesticide resistanceon April 23, 2024 at 11:39 am
One UC Riverside scientist has been awarded $1.9 million to decode nematodes’ attack strategies, and combat resistance issues.
- Sluggish uptake of new antibiotics threatens future development and supply for highly resistant infectionson April 19, 2024 at 6:00 am
A large retrospective cohort pharmacoepidemiologic study found that despite approval by the U.S. Food and Drug Administration (FDA) for seven new gram-negative antibiotics between 2014 and 2019, ...
via Bing News